Premium
Magmaris very late in‐scaffold restenosis: Has the “black boxes” nightmare come back?
Author(s) -
Bayón Jeremías,
SantásÁlvarez Melisa,
OcaranzaSánchez Raymundo,
GonzálezJuanatey Carlos
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28608
Subject(s) - medicine , restenosis , scaffold , bioresorbable scaffold , optical coherence tomography , nightmare , stent , everolimus , radiology , biomedical engineering , percutaneous coronary intervention , myocardial infarction , psychiatry
Magnesium Bioresorbable Scaffold (Magmaris, Biotronik) is a device with promising outcomes at 24 months of follow up. Previous studies with first generation, everolimus‐eluting Bioresorbable Vascular Scaffold (Absorb, Abbott) showed that very late restenosis seems to be attributed to pure intrascaffold tissue growth but very late. Magmaris very late restenosis has not been previously published, probably because of the 95% of resorption at 12 months. We present in‐scaffold very late restenosis within Magmaris, with Optical Coherence Tomography, highlighting mechanism of degradation and in scaffold “neo‐tissue” growth.